On June 7, 2016 Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, reported that it will present its TTI-621 (SIRPaFc) immune checkpoint inhibitor program at the European Hematology Association (EHA) (Free EHA Whitepaper) 21st Annual Congress, to be held in Copenhagen from June 9- 12 (Press release, Trillium Therapeutics, JUN 7, 2016, View Source [SID:1234513089]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of Trillium’s presentation are as follows:

Presentation Type: Electronic Poster
Abstract #: E1373
Title: The CD47-blocking Cancer Immunotherapeutic TTI-621 has Anti-Tumor Effects Across a Broad Range of Hematological Malignancies